Comparison of ELISA- and SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosis

Comparison of ELISA- and SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosis

Abstract Background Blood-based amyloid biomarkers may provide a non-invasive, cost-effective and scalable manner for detecting cerebral amyloidosis in early disease stages. Methods In this prospective cross-sectional study, we quantified plasma Aβ1–42/Aβ1–40 ratios with both routinely available ELI...

Full description

Bibliographic Details
Main Authors: Steffi De Meyer, Jolien M. Schaeverbeke, Inge M. W. Verberk, Benjamin Gille, Maxim De Schaepdryver, Emma S. Luckett, Silvy Gabel, Rose Bruffaerts, Kimberley Mauroo, Elisabeth H. Thijssen, Erik Stoops, Hugo M. Vanderstichele, Charlotte E. Teunissen, Rik Vandenberghe, Koen Poesen
Format: Article
Language:English
Published: BMC 2020-12-01
Series:Alzheimer’s Research & Therapy
Subjects:
Preclinical Alzheimer’s disease
Plasma
β-Amyloid
Biomarkers
Immunoassay
ELISA
Online Access:https://doi.org/10.1186/s13195-020-00728-w

Internet

https://doi.org/10.1186/s13195-020-00728-w

Similar Items